GSK’s Breo Ellipta Approved With COPD Airflow Obstruction, Exacerbation Claims
This article was originally published in The Pink Sheet Daily
Executive Summary
Once-daily dosing provides a convenience advantage over the other inhaled corticosteroid/long-acting beta-agonist combination products on the COPD market: GlaxoSmithKline’s own Advair and AstraZeneca’s Symbicort.
You may also be interested in...
FDA’s Pediatric Data-Extrapolation Policies Questioned At Asthma Panel
Should using adult data to label a product for kids be ‘a judgment call?’ Advisory committee asks whether FDA needs more explicit criteria during review of GSK’s Breo Ellipta.
GSK’s Breo Breathing A Little Easier In Asthma, But More Studies Ahead
FDA advisory committee votes recommends Breo Ellipta for asthma in adults with post-approval safety study, but panel wants additional premarket efficacy and safety data for adolescents.
Breo Ellipta’s Adolescent Data Could Be Highest Hurdle For Asthma Claim
FDA’s Pulmonary-Allergy Drugs and Drug Safety and Risk Management advisors will cast separate votes March 19 on GSK’s ICS/LABA combo for patients 12-17 and for adults 18 and older.